These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35200425)

  • 1. COVID-19 Vaccines: An Overview of Different Platforms.
    Kudlay D; Svistunov A
    Bioengineering (Basel); 2022 Feb; 9(2):. PubMed ID: 35200425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 Vaccines: An Updated Overview of Different Platforms.
    Kudlay D; Svistunov A; Satyshev O
    Bioengineering (Basel); 2022 Nov; 9(11):. PubMed ID: 36421115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use.
    Vasireddy D; Atluri P; Malayala SV; Vanaparthy R; Mohan G
    J Clin Med Res; 2021 Apr; 13(4):204-213. PubMed ID: 34007358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.
    Li Q; Wang J; Tang Y; Lu H
    Drug Discov Ther; 2021; 15(3):118-123. PubMed ID: 34234059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines.
    Machado BAS; Hodel KVS; Fonseca LMDS; Pires VC; Mascarenhas LAB; da Silva Andrade LPC; Moret MA; Badaró R
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines.
    Basheeruddin Asdaq SM; Jomah S; Rabbani SI; Alamri AM; Salem Alshammari SK; Duwaidi BS; Alshammari MS; Alamri AS; Alsanie WF; Alhomrani M; Sreeharsha N; Imran M
    Can J Infect Dis Med Microbiol; 2022; 2022():6913772. PubMed ID: 35186175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brief review of the mRNA vaccines COVID-19.
    Vitiello A; Ferrara F
    Inflammopharmacology; 2021 Jun; 29(3):645-649. PubMed ID: 33932192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The COVID-19 pandemic: viral variants and vaccine efficacy.
    Ciotti M; Ciccozzi M; Pieri M; Bernardini S
    Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
    Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
    J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging issues related to COVID-19 vaccination in patients with cancer.
    Saini KS; Martins-Branco D; Tagliamento M; Vidal L; Singh N; Punie K; Saini ML; Chico I; Curigliano G; de Azambuja E; Lambertini M
    Oncol Ther; 2021 Dec; 9(2):255-265. PubMed ID: 34137014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development.
    Ilyichev AA; Orlova LA; Sharabrin SV; Karpenko LI
    Vavilovskii Zhurnal Genet Selektsii; 2020 Nov; 24(7):802-807. PubMed ID: 33959697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Nanoparticle-Enabled Success of COVID-19 mRNA Vaccines and the Promise of Microneedle Platforms for Pandemic Vaccine Response.
    Kapnick SM
    DNA Cell Biol; 2022 Jan; 41(1):25-29. PubMed ID: 34958232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.